|D053717||Pneumonia, Ventilator-Associated NIH||0.38|
|D011024||Pneumonia, Viral NIH||0.17|
There is one clinical trial.
2019 new coronavirus (2019-nCoV) infected pneumonia, namely severe acute respiratory infection (SARI) has caused global concern and emergency. There is a lack of effective targeted antiviral drugs, and symptomatic supportive treatment is still the current main treatment for SARI. Vitamin C is significant to human body and plays a role in reducing inflammatory response and preventing common cold. In addtion, a few studies have shown that vitamin C deficiency is related to the increased risk and severity of influenza infections. We hypothize that Vitamin C infusion can help improve the prognosis of patients with SARI. Therefore, it is necessary to study the clinical efficacy and safety of vitamin C for the clinical management of SARI through randomized controlled trials during the current epidemic of SARI.
Description: days without ventilation support during 28 days after patients' enrollmentMeasure: Ventilation-free days Time: on the day 28 after enrollment
Description: wether the patient survivesMeasure: 28-days mortality Time: on the day 28 after enrollment
Description: days of the patients staying in the ICUMeasure: ICU length of stay Time: on the day 28 after enrollment
Description: the rate of CPRMeasure: Demand for first aid measuments Time: on the day 28 after enrollment
Description: days of using vasopressorsMeasure: Vasopressor days Time: on the day 28 after enrollment
Description: P O2/Fi O2 which reflects patients' respiratory functionMeasure: Respiratory indexes Time: on the day 10 and 28 after enrollment
Description: Ecmo or ventilatorMeasure: Ventilator parameters Time: on the day 10 and 28 after enrollment
Description: Acute Physiology and Chronic Health EvaluationMeasure: APACHE II scores Time: on the day 10 after enrollment
Description: Sepsis-related Organ Failure AssessmentMeasure: SOFA scores Time: on the day 10 after enrollment